Seeking Alpha

Recursion Pharmaceuticals, Inc. (RXRX) Q4 2023 Earnings Call Transcript

Hi, everybody. I’m Chris Gibson, Co-Founder and CEO of Recursion, and I am really excited to welcome you to our first ever Learnings Call here at Recursion. So what is a learnings call and why are we ...
Hosted on MSN

Recursion Pharmaceuticals call volume above normal and directionally bullish

Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 35,100 calls trading, 5x expected, and implied vol increasing almost 42 points to 161.96%. 10/24 weekly 7 calls and 10/24 weekly 7 ...
Seeking Alpha

Recursion Pharmaceuticals Q4: Why My December Buy Call Was Too Optimistic

Recursion Pharmaceuticals, Inc. (RXRX), the self-styled "clinical-stage TechBio company with a mission to decode biology to radically improve lives" (Source: 2025 annual report/10-K filing), reported ...
Nasdaq

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Multiple clinical programs from Recursion’s first generation platform are on track to read out Phase 2 data in H2 2024 and H1 2025 with additional second generation programs approaching IND in the ...
The Motley Fool

Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now?

Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...